NCT03684980View on ClinicalTrials.gov

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 14, 2018

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Central Nervous System Lymphoma
Interventions
DRUG

Methotrexate

(Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m\^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2

DRUG

Rituximab

Patients will be treated with rituximab 500 mg/m\^2.

DRUG

leucovorin

Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.

DRUG

Glucarpidase

Glucarpidase 2000 units. Arm E 1000 units.

Trial Locations (11)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester, Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau, Uniondale

11725

RECRUITING

Memorial Sloan Kettering Commack, Commack

35294

ACTIVE_NOT_RECRUITING

University of Alabama at Birmingham, Birmingham

44195

RECRUITING

Cleveland Clinic (Data Collection and Specimen Collection), Cleveland

45229

NOT_YET_RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

02115

ACTIVE_NOT_RECRUITING

Dana Farber Cancer Institute (Data Collection and Specimen Analysis), Boston

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth, Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
collaborator

University of Alabama at Birmingham

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER